BR112017020374A2 - compostos bicíclicos fundidos para o tratamento de doença - Google Patents
compostos bicíclicos fundidos para o tratamento de doençaInfo
- Publication number
- BR112017020374A2 BR112017020374A2 BR112017020374A BR112017020374A BR112017020374A2 BR 112017020374 A2 BR112017020374 A2 BR 112017020374A2 BR 112017020374 A BR112017020374 A BR 112017020374A BR 112017020374 A BR112017020374 A BR 112017020374A BR 112017020374 A2 BR112017020374 A2 BR 112017020374A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treatment
- fused bicyclic
- bicyclic compounds
- compounds
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138725P | 2015-03-26 | 2015-03-26 | |
| PCT/IB2016/000606 WO2016151403A1 (en) | 2015-03-26 | 2016-03-25 | Fused bicyclic compounds for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017020374A2 true BR112017020374A2 (pt) | 2018-06-05 |
Family
ID=56072361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020374A BR112017020374A2 (pt) | 2015-03-26 | 2016-03-25 | compostos bicíclicos fundidos para o tratamento de doença |
Country Status (16)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021107054A (ru) * | 2015-03-26 | 2021-03-31 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболевания |
| JP2019520335A (ja) * | 2016-05-25 | 2019-07-18 | アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． | 疾患治療用の縮合二環式化合物 |
| MX2018014024A (es) * | 2016-05-25 | 2019-08-29 | Akarna Therapeutics Ltd | Terapias de combinación con moduladores del receptor x farnesoide (fxr). |
| BR112019025228A2 (pt) * | 2017-06-02 | 2020-06-23 | Akarna Therapeutics, Ltd. | Compostos bicíclicos fundidos |
| CN108264474B (zh) * | 2018-02-09 | 2019-10-25 | 浙江师范大学 | 一种色胺及其衍生物的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| WO2005009387A2 (en) * | 2003-07-23 | 2005-02-03 | X-Ceptor Therapeutics Inc. | Azepine derivatives as pharmaceutical agents |
| EP1776112A4 (en) | 2004-08-10 | 2009-11-25 | Exelixis Inc | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS |
| WO2006109633A1 (ja) | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
| WO2007070796A1 (en) * | 2005-12-15 | 2007-06-21 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| US20090131409A1 (en) * | 2007-10-22 | 2009-05-21 | Wyeth | 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| US20090137554A1 (en) | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| JP2012503654A (ja) * | 2008-09-26 | 2012-02-09 | ワイス・エルエルシー | １，２，３，６−テトラヒドロアゼピノ［４，５−ｂ］インドール−５−カルボキシレート核内受容体阻害剤 |
| CA2968434A1 (en) * | 2014-11-21 | 2016-05-26 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| RU2741387C2 (ru) * | 2014-12-22 | 2021-01-25 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболевания |
| RU2021107054A (ru) * | 2015-03-26 | 2021-03-31 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболевания |
-
2016
- 2016-03-25 RU RU2021107054A patent/RU2021107054A/ru unknown
- 2016-03-25 EP EP20158977.7A patent/EP3715348A1/en not_active Withdrawn
- 2016-03-25 HK HK18109050.8A patent/HK1249756A1/zh unknown
- 2016-03-25 WO PCT/IB2016/000606 patent/WO2016151403A1/en not_active Ceased
- 2016-03-25 CA CA2980394A patent/CA2980394A1/en not_active Abandoned
- 2016-03-25 RU RU2017137366A patent/RU2017137366A/ru unknown
- 2016-03-25 SG SG10201908881P patent/SG10201908881PA/en unknown
- 2016-03-25 KR KR1020177030777A patent/KR20180003545A/ko not_active Ceased
- 2016-03-25 BR BR112017020374A patent/BR112017020374A2/pt not_active IP Right Cessation
- 2016-03-25 AU AU2016238523A patent/AU2016238523A1/en not_active Abandoned
- 2016-03-25 MX MX2017012342A patent/MX370897B/es active IP Right Grant
- 2016-03-25 SG SG11201707610PA patent/SG11201707610PA/en unknown
- 2016-03-25 JP JP2017550113A patent/JP6843061B2/ja not_active Expired - Fee Related
- 2016-03-25 CN CN201680029952.3A patent/CN107912042A/zh active Pending
- 2016-03-25 EP EP16724699.0A patent/EP3274350A1/en not_active Withdrawn
-
2017
- 2017-09-18 IL IL254572A patent/IL254572A0/en unknown
- 2017-09-25 US US15/714,013 patent/US10421759B2/en active Active
- 2017-09-25 CL CL2017002405A patent/CL2017002405A1/es unknown
- 2017-10-18 CO CONC2017/0010621A patent/CO2017010621A2/es unknown
-
2019
- 2019-09-19 US US16/575,965 patent/US20200079782A1/en not_active Abandoned
-
2020
- 2020-10-12 AU AU2020256301A patent/AU2020256301A1/en not_active Abandoned
- 2020-11-17 US US17/099,864 patent/US20210214362A1/en not_active Abandoned
-
2022
- 2022-04-19 US US17/724,138 patent/US20230002394A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016151403A1 (en) | 2016-09-29 |
| MX370897B (es) | 2020-01-09 |
| JP2018510876A (ja) | 2018-04-19 |
| US20180118752A1 (en) | 2018-05-03 |
| EP3274350A1 (en) | 2018-01-31 |
| CL2017002405A1 (es) | 2018-04-27 |
| HK1249756A1 (zh) | 2018-11-09 |
| CA2980394A1 (en) | 2016-09-29 |
| SG11201707610PA (en) | 2017-10-30 |
| US10421759B2 (en) | 2019-09-24 |
| IL254572A0 (en) | 2017-11-30 |
| AU2020256301A1 (en) | 2020-11-05 |
| US20230002394A1 (en) | 2023-01-05 |
| CO2017010621A2 (es) | 2018-01-31 |
| RU2017137366A3 (cg-RX-API-DMAC10.html) | 2019-07-17 |
| RU2021107054A (ru) | 2021-03-31 |
| CN107912042A (zh) | 2018-04-13 |
| EP3715348A1 (en) | 2020-09-30 |
| MX2017012342A (es) | 2018-06-11 |
| RU2017137366A (ru) | 2019-04-26 |
| US20210214362A1 (en) | 2021-07-15 |
| JP6843061B2 (ja) | 2021-03-17 |
| SG10201908881PA (en) | 2019-11-28 |
| AU2016238523A1 (en) | 2017-11-09 |
| KR20180003545A (ko) | 2018-01-09 |
| US20200079782A1 (en) | 2020-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| LT3594238T (lt) | Antikūno kompozicijos, skirtos navikų gydymui | |
| CL2019001381A1 (es) | Método para el tratamiento de glomeruloesclerosis segmentaria focal. | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
| MX391040B (es) | Formulacion de alta concentracion. | |
| BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
| BR112018012883A2 (pt) | novos anticorpos anti-upk1b e métodos de uso | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| BR112018003928A2 (pt) | métodos para o tratamento de doenças | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 | |
| MX390653B (es) | Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica. | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
| EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| BR112018009745A2 (pt) | compostos heterocíclicos para o tratamento de doença | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| BR112017019176A2 (pt) | processos para a preparação de fluorocetolídeos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2715 DE 17/01/2023. |